by Crestone, Inc. | Apr 28, 2022 | Events
2022 National C. Diff Advocacy Summit Presentation Details Crestone presents at the largest gathering of C. diff advocates and allies in industry, academia and policymaking in the country. Find out more about this event and the Peggy Lillis foundation by visiting...
by Crestone, Inc. | Nov 4, 2021 | Events
C. diff International Conference & Health EXPO Presentation Details Crestone, Inc. presents at the C. diff. International Conference & Health EXPO.
by Crestone, Inc. | Jun 8, 2021 | Press Releases
June 8, 2021 – Announcement: Crestone, Inc. joins the Antimicrobials Working Group to Combat Drug Resistant Infections June 8, 2021. The Antimicrobials Working Group (AWG) announced today the addition of Crestone, Inc. to its coalition of companies with the...
by Crestone, Inc. | Jun 7, 2021 | Press Releases
June 7, 2021 – Announcement: Crestone, Inc. Enrolls First Patient in Phase 2 Clinical Trial for Novel Antibiotic CRS3123 to Treat C. difficile Infections. FDA also Grants CRS3123 ‘Qualified Infectious Disease Product’ (QIDP) and ‘Fast Track’ Designations. Learn...
by Crestone, Inc. | Jul 1, 2020 | Press Releases
July 1, 2020 – Announcement: Crestone, Inc. Secures NIH Funding for Development Through Phase 1 of Novel Antibiotic Candidate CRS0540, A Novel Inhibitor of DNA Replication in Gram-positive Pathogens. Learn More:...
